An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune pathophysiology of immune thrombocytopenia (ITP) by modulating B cells, ...
—Two recent studies from the same Netherlands-based research team shed new light on predicting the disease course of immune thrombocytopenia (ITP) in children and adolescents, which can help to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results